OR WAIT null SECS
David Deere is the chief commercialization officer for PaizaBio, a US-based contract manufacturing organization and consulting group with in-country aseptic fill-and-finish operations in Hangzhou, China. Deere is a veteran global pharmaceutical executive whose career path includes Valeant Pharmaceuticals International, F. Hoffman-La Roche and Genentech.
New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.
New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China. To compete in this resource-intensive manufacturing process that requires large volume capacity and a technically trained labor force, it is logical pharmaceutical companies will turn to contract manufacturing in China to meet strategic sourcing requirements.